Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Max N. Wallace is Director at Humacyte. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 12, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
HumacyteHUMA
Jun 11, 202680Kdisclosed Jun 12
DetailsOfficial recordMax N. Wallace bought shares on the open market in 2024, and has not bought since 2024.
Max N. Wallace reported 2 open-market purchases and 0 sales since 2024; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $50K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Max N. Wallace bought shares on the open market in 2024, and has not bought since 2024.
In SEC filings since 2024: the latest open-market purchase is from 2024; no open-market sale is on record.
Humacyte (HUMA), from 2024 to 2024: 2 purchases and 0 sales.
Max N. Wallace reported 2 open-market purchases and 0 sales here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.